Total Payments
$116,429
2024 Payments
$10,485
Companies
40
Transactions
492
Medicare Patients
7,484
Medicare Billing
$559,897
Payment Breakdown by Category
Research$108,060 (92.8%)
Food & Beverage$7,365 (6.3%)
Other$1,000 (0.9%)
Education$3.29 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $108,060 | 9 | 92.8% |
| Food and Beverage | $7,365 | 478 | 6.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,000 | 4 | 0.9% |
| Education | $3.29 | 1 | 0.0% |
Payments by Type
Research
$108,060
9 transactions
General
$8,369
483 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $108,060 | 9 | $0 (2024) |
| Abbott Laboratories | $1,593 | 89 | $0 (2024) |
| Tandem Diabetes Care, Inc. | $1,088 | 10 | $0 (2023) |
| Novo Nordisk Inc | $918.74 | 91 | $0 (2024) |
| Insulet Corporation | $512.40 | 31 | $0 (2024) |
| Lilly USA, LLC | $403.62 | 23 | $0 (2024) |
| Horizon Therapeutics plc | $372.55 | 17 | $0 (2023) |
| SANOFI-AVENTIS U.S. LLC | $355.10 | 21 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $348.56 | 17 | $0 (2024) |
| Medtronic, Inc. | $335.08 | 18 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $10,485 | 73 | Eli Lilly and Company ($9,216) |
| 2023 | $1,444 | 80 | Insulet Corporation ($269.50) |
| 2022 | $1,449 | 88 | Abbott Laboratories ($284.78) |
| 2021 | $627.82 | 36 | Abbott Laboratories ($142.61) |
| 2020 | $6,402 | 17 | Eli Lilly and Company ($6,178) |
| 2019 | $11,312 | 84 | Eli Lilly and Company ($10,143) |
| 2018 | $61,730 | 64 | Eli Lilly and Company ($60,493) |
| 2017 | $22,978 | 50 | Eli Lilly and Company ($22,031) |
All Payment Transactions
492 individual payment records from CMS Open Payments — Page 1 of 20
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | Insulet Corporation | Omnipod (Device) | Food and Beverage | Cash or cash equivalent | $23.82 | General |
| Category: Insulin Pump | ||||||
| 12/11/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $24.90 | General |
| Category: Diabetes Care | ||||||
| 12/10/2024 | Medtronic, Inc. | MINIMED 780G (Device) | Food and Beverage | In-kind items and services | $15.43 | General |
| Category: Durable Pump | ||||||
| 12/10/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $13.16 | General |
| Category: Endocrinology | ||||||
| 12/09/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $20.35 | General |
| Category: Diabetes Care | ||||||
| 12/09/2024 | Medtronic, Inc. | MINIMED 780G (Device) | Food and Beverage | In-kind items and services | $10.53 | General |
| Category: Durable Pump | ||||||
| 12/04/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $18.71 | General |
| Category: Diabetes | ||||||
| 11/26/2024 | Amneal Pharmaceuticals LLC | UNITHROID (Drug) | Food and Beverage | In-kind items and services | $15.50 | General |
| Category: ENDOCRINOLOGY | ||||||
| 11/20/2024 | Alexion Pharmaceuticals, Inc. | STRENSIQ (Biological) | Food and Beverage | In-kind items and services | $18.75 | General |
| Category: Rare Disease | ||||||
| 11/19/2024 | Medtronic, Inc. | MINIMED 780G (Device) | Food and Beverage | In-kind items and services | $14.66 | General |
| Category: Durable Pump | ||||||
| 11/13/2024 | Neurocrine Biosciences, Inc. | — | Food and Beverage | In-kind items and services | $25.35 | General |
| 11/07/2024 | Medtronic, Inc. | MINIMED 780G (Device) | Food and Beverage | In-kind items and services | $22.09 | General |
| Category: Durable Pump | ||||||
| 10/28/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus, Tresiba | Food and Beverage | In-kind items and services | $13.94 | General |
| Category: Diabetes | ||||||
| 10/24/2024 | Xeris Pharmaceuticals, Inc. | RECORLEV (Drug) | Food and Beverage | In-kind items and services | $22.90 | General |
| Category: Adrenal steroidogenesis inhibitor | ||||||
| 10/22/2024 | Medtronic, Inc. | MINIMED 780G (Device) | Food and Beverage | In-kind items and services | $31.12 | General |
| Category: Durable Pump | ||||||
| 10/22/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $14.15 | General |
| 10/21/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $20.39 | General |
| Category: Diabetes | ||||||
| 10/14/2024 | Medtronic, Inc. | MINIMED 780G (Device) | Food and Beverage | In-kind items and services | $25.57 | General |
| Category: Durable Pump | ||||||
| 10/09/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $24.54 | General |
| Category: Diabetes Care | ||||||
| 10/09/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $18.07 | General |
| Category: Diabetes Care | ||||||
| 10/01/2024 | Medtronic, Inc. | MINIMED 780G (Device) | Food and Beverage | In-kind items and services | $9.50 | General |
| Category: Durable Pump | ||||||
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $9,216.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE | ||||||
| 09/19/2024 | Insulet Corporation | Omnipod (Device) | Food and Beverage | Cash or cash equivalent | $20.65 | General |
| Category: Insulin Pump | ||||||
| 09/16/2024 | Insulet Corporation | Omnipod (Device) | Food and Beverage | Cash or cash equivalent | $16.19 | General |
| Category: Insulin Pump | ||||||
| 09/16/2024 | Medtronic, Inc. | MINIMED 780G (Device) | Food and Beverage | In-kind items and services | $12.84 | General |
| Category: Durable Pump | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND COMPARISON OF LY900014 TO INSULIN LISPRO WITH AN OPEN-LABEL POSTPRANDIAL LY900014 TREATMENT GROUP, IN COMBINATION WITH INSULIN GLARGINE OR INSULIN DEGLUDEC, IN ADULTS WITH TYPE 1 DIABETES PRONTO-T1D | Eli Lilly and Company | $90,859 | 4 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE | Eli Lilly and Company | $9,216 | 1 |
| A RANDOMIZED, PHASE 3, OPEN-LABEL TRIAL COMPARING THE EFFECT OF LY3298176 VERSUS TITRATED INSULIN DEGLUDEC ON GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES | Eli Lilly and Company | $5,555 | 2 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) | Eli Lilly and Company | $2,430 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 731 | 1,479 | $295,790 | $116,318 |
| 2022 | 16 | 1,467 | 2,250 | $296,809 | $111,349 |
| 2021 | 23 | 2,509 | 4,722 | $421,523 | $170,564 |
| 2020 | 24 | 2,777 | 4,693 | $331,807 | $161,667 |
Total Patients
7,484
Total Services
13,144
Medicare Billing
$559,897
Procedure Codes
69
All Medicare Procedures & Services
69 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 503 | 1,099 | $252,770 | $99,429 | 39.3% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2023 | 85 | 212 | $13,780 | $5,613 | 40.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 62 | 86 | $13,760 | $4,921 | 35.8% |
| 76536 | Ultrasound scan of head and neck soft tissue | Office | 2023 | 55 | 56 | $8,400 | $4,489 | 53.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 14 | 14 | $4,200 | $1,424 | 33.9% |
| 77080 | Dxa bone density measurement of hip, pelvis, spine | Office | 2023 | 12 | 12 | $2,880 | $441.60 | 15.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 437 | 992 | $228,160 | $86,500 | 37.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 77 | 110 | $17,600 | $6,168 | 35.0% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2022 | 63 | 160 | $10,400 | $4,175 | 40.1% |
| 76536 | Ultrasound scan of head and neck soft tissue | Office | 2022 | 46 | 47 | $7,050 | $3,742 | 53.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 12 | 12 | $3,600 | $1,626 | 45.2% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2022 | 84 | 89 | $5,353 | $1,491 | 27.9% |
| 83036 | Hemoglobin a1c level | Office | 2022 | 128 | 149 | $5,178 | $1,443 | 27.9% |
| 80061 | Blood test, lipids (cholesterol and triglycerides) | Office | 2022 | 90 | 95 | $4,558 | $1,269 | 27.8% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2022 | 97 | 102 | $3,861 | $1,074 | 27.8% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 11 | 19 | $2,470 | $1,042 | 42.2% |
| 84439 | Thyroxine (thyroid chemical), free | Office | 2022 | 70 | 75 | $2,423 | $674.52 | 27.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 173 | 211 | $1,583 | $631.59 | 39.9% |
| 82044 | Urine microalbumin (protein) analysis | Office | 2022 | 64 | 69 | $690.00 | $428.73 | 62.1% |
| 82306 | Vitamin d-3 level | Office | 2022 | 14 | 14 | $1,484 | $413.80 | 27.9% |
| 82570 | Creatinine level to test for kidney function or muscle injury | Office | 2022 | 64 | 69 | $1,279 | $356.47 | 27.9% |
| 80048 | Blood test, basic group of blood chemicals (calcium, total) | Office | 2022 | 37 | 37 | $1,121 | $312.46 | 27.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 455 | 1,028 | $220,480 | $93,661 | 42.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 150 | 311 | $38,240 | $17,618 | 46.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 127 | 179 | $26,120 | $10,954 | 41.9% |
About Dr. J Magee, M.D
Dr. J Magee, M.D is a Specialist healthcare provider based in Jacksonville, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/13/2005. The National Provider Identifier (NPI) number assigned to this provider is 1801890389.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. J Magee, M.D has received a total of $116,429 in payments from pharmaceutical and medical device companies, with $10,485 received in 2024. These payments were reported across 492 transactions from 40 companies. The most common payment nature is "" ($108,060).
As a Medicare-enrolled provider, Magee has provided services to 7,484 Medicare beneficiaries, totaling 13,144 services with total Medicare billing of $559,897. Data is available for 4 years (2020–2023), covering 69 distinct procedure/service records.
Ad
Practice Information
- Specialty Specialist
- Other Specialties Diabetes & Metabolism
- Location Jacksonville, FL
- Active Since 06/13/2005
- Last Updated 02/04/2025
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1801890389
Products in Payments
- t-slim insulin pump (Device) $1,000
- FREESTYLE LIBRE 3 (Device) $552.34
- Omnipod (Device) $512.40
- FreeStyle Libre (Device) $418.00
- Ozempic (Drug) $381.32
- TEPEZZA (Drug) $359.20
- Kerendia (Drug) $348.56
- FREESTYLE LIBRE 2 (Device) $299.35
- V-GO (Device) $282.13
- MINIMED 780G (Device) $219.16
- AFREZZA (Drug) $183.88
- INVOKANA (Drug) $177.84
- MOUNJARO (Drug) $170.60
- Repatha (Biological) $157.24
- GVOKE PFS (Drug) $152.51
- Rybelsus (Drug) $152.04
- Korlym (Drug) $147.73
- FreeStyle Libre blood glucose Flash Monitoring System (Device) $141.78
- JARDIANCE (Drug) $133.27
- Tirosint (Drug) $130.70
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Jacksonville
Dr. Andrew Cannestra, Md, MD
Specialist — Payments: $1.6M
Specialist $1.6M
Dr. David Sutton, M.d, M.D
Specialist — Payments: $1.3M
Specialist $1.3M
Richard Heekin, Md, MD
Specialist — Payments: $173,723
Specialist $173,723
Dr. Arun Gulani, M.d, M.D
Specialist — Payments: $129,235
Specialist $129,235
Dr. Khurram Wadud, M.d, M.D
Specialist — Payments: $121,636
Specialist $121,636
Dr. Mary Pentel, M.d, M.D
Specialist — Payments: $60,033
Specialist $60,033